H4 Update on 13-Valent Pneumococcal Conjugate Vaccine (PCV13)

Presenters in this workshop will discuss the ACIP’s recommendation for use of recently licensed 13-valent pneumococcal conjugate vaccine and provide guidance for for providers regarding transition from PCV7 to PCV13.
Wednesday, April 21, 2010: 11:00 AM-12:00 PM
International Ballroom South
Pekka Nuorti
11:20 AM
Introductory Remarks
11:00 AM
ACIP Recommendations for Use of PCV13
Pekka Nuorti, MD, DSc, Medical Epidemiologist, Centers for Disease Control and Prevention
11:25 AM
PCV13 Program Implementation—Guidance for Providers Regarding Transition From PCV7 to PCV13
Abigail Shefer, MD, MPH, Associate Director for Science, Centers for Disease Control and Prevention
11:45 AM
See more of: Submissions